



PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Hembrough et al.

Serial No. 10/608,886

Filed: June 26, 2003

For: Compositions and Methods Comprising
Protein Activated Receptor Antagonists

)
)
)
) Art Unit: 1614
)
)
)
)
)
)

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Kilpatrick Stockton LLP
1100 Peachtree Street, Ste. 2800
Atlanta, Georgia 30309-4530
(404) 815-6500
Our Docket: 05213-3041 (43170-286877)


Respectfully submitted,

Sima Singadia Kulkarni
Sima Singadia Kulkarni
Reg. No. 43,732

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 24 day of August, 2004

Sima Singadia Kulkarni
Sima Singadia Kulkarni - Reg. No. 43,732

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application No.	10/608,886
Filing Date	06/26/2003
First Named Inventor	Hembrough et al.
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	05213-3041 (43170-286877)

Sheet 1 of 3

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number ⁴	Kind Code ² (if known)			
	1	5,001,116		Folkman et al.	03/19/1991	
	2	5,629,327		D'Amato	05/13/1997	
	3	5,639,725		O'Reilly et al.	06/17/1997	
	4	5,733,876		O'Reilly et al.	03/31/1998	
	5	5,792,845		O'Reilly et al.	08/11/1998	
	6	5,854,205		O'Reilly et al.	12/29/1998	
	7	5,919,459	A	Nacy et al.	07/06/1999	
	8	5,981,471		Papathanassiu et al.	11/09/1999	
	9	6,346,510	B1	O'Reilly et al.	02/12/2002	
	10	6,413,513	B1	Holaday, John	07/02/2002	

Examiner
SignatureDate
Considered

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known					
				Application No.		10/608,886			
				Filing Date		06/26/2003			
				First Named Inventor		Hembrough et al.			
				Group Art Unit		1614			
				Examiner Name		Unassigned			
Sheet	2	of	3	Attorney Docket Number				05213-3041 (43170-286877)	
FOREIGN PATENT DOCUMENTS									
Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
		Office ³	Number ⁴	Kind Code ⁵ (if known)					
	11	WO	01/52883	A1	Amgen, Inc.	01/19/2001			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known		
				Application No.	10/608,886	
				Filing Date	06/26/2003	
				First Named Inventor	Hembrough et al.	
				Group Art Unit	1614	
				Examiner Name	Unassigned	
Sheet	3	of	3	Attorney Docket Number		05213-3041 (43170-286877)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	12	Author: AL-ANI et al. Title: Proteinase-Activated Receptor 2 (PAR2): Development of a Ligand-Binding Assay Correlating with Activation of PAR2by PAR1 - and PAR2-Derived Peptide Ligands (Abstract only) Publ: <u>Journal of Pharmacology</u> Vol/Iss: 290 (2) Pages: 753-760 Date: 08/1999	
	13	Author: BACH Title: Initiation of Coagulation by Tissue Factor Publ: <u>CRC Crit Rev Biochem</u> Vol/Iss: 23 (4) Pages: 339-368 Date: 1988	
	14	Author: CRUM, R. et al. Title: A New Class of Steroids Inhibits Angiogenesis in the Presence of Heparin or a Heparin Fragment Publ: <u>Science</u> Vol/Iss: 230 Pages: 1375-1378 Date: 12/20/85	
	15	Author: ENJOJI, K. et al. Title: Effect of Heparin on the Inhibition of Factor Xa by Tissue Factor Pathway Inhibitor: A Segment, Gly ²¹² - Phe ²⁴³ , of the third Kunitz Domain is a Heparin-Binding Site Publ: <u>Biochemistry</u> Vol/Iss: 34 (17) Pages: 5725-5735 Date: 1995	
	16	Author: FOLKMAN, J. Title: Tumor Angiogenesis: Therapeutic Implications Publ: <u>New England Journal of Medicine</u> Vol/Iss: 285 (21) Pages: 1182-1186 Date: 11/18/71	
	17	Author: MILIA et al. Title: Protease-activated Receptor-2 Stimulates Angiogenesis and Accelerates Hemodynamic Recovery in a Mouse Model of Hindlimb Ischemia (Abstract only) Publ: <u>Circ. Res.</u> Vol/Iss: 91 (4) Pages: 346-352 Date: 2002	
	18	Author: NOVOTNY, W.F. et al. Title: Purification and Characterization of the Lipoprotein-Associated Coagulation Inhibitor from Human Plasma Publ: <u>Journal of Biological Chemistry</u> Vol/Iss: 264 Pages: 18832-18837 Date: 11/05/89	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.